Oncolytics Biotech (ONCY) Total Liabilities (2009 - 2025)

Oncolytics Biotech (ONCY) has 17 years of Total Liabilities data on file, last reported at $11.4 million in Q4 2025.

• On a quarterly basis, Total Liabilities rose 11.93% year-over-year to $11.4 million in Q4 2025; TTM through Dec 2025 was $11.4 million, a 11.93% increase from a year earlier, with the FY2025 full-year figure at $11.4 million, up 12.43% from the prior year.
• Total Liabilities for Q4 2025 stood at $11.4 million, up from $10.9 million in the prior quarter.
• Over the last five years, Total Liabilities for ONCY reached as high as $12.7 million in Q3 2023 and fell as low as $7.1 million in Q1 2023.
• Historically, Total Liabilities has averaged $8.9 million across 5 years, with a median of $8.2 million in 2022.
• Across the five-year window, Total Liabilities sank 32.43% in 2021 and soared 57.23% in 2023, its largest moves.
• Year by year, Total Liabilities stood at $7.8 million in 2021, then increased by 2.84% to $8.0 million in 2022, then gained by 3.62% to $8.3 million in 2023, then climbed by 22.97% to $10.2 million in 2024, then climbed by 11.93% to $11.4 million in 2025.
• Per Business Quant data, the three most recent Total Liabilities figures were $11.4 million in Q4 2025, $10.9 million in Q3 2025, and $10.0 million in Q2 2025.